CV DV Dosar

1
CURRICULUM VITAE
Vasile Daniel
Conferențiar universitar
Medic primar psihiatru
Doctor in stiinte medicale
Șef Clinică Psihiatrie
DATA NAȘTERII - 29.04.1963
STUDII - Facultatea de Medicină Militară, I.M.F. București, 1987
LIMBI STRĂINE CUNOSCUTE:
-Engleza nivel C1 conform Cadrului Comun European de Referinţă (autoevaluare);

-Franceză nivel B2 conform Cadrului Comun European de Referinţă (autoevaluare).
EVOLUȚIE PROFESIONALĂ
-Medic stagiar in Spitalul Militar Central 1987-1990

-Medic secundar prin concurs specialitatea psihiatrie, Clinica Psihiatrie - Spitalul Prof.
Gh. Marinescu - Bucuresti 1990
-Medic specialist psihiatru, 1994
-Participant la misiunea “Restore Hope”, Somalia, 1994
-Medic primar psihiatru 1998
-Doctor in științe medicale, 2001 (U.M.F. Carol Davila, București), coordonator Acad.
Prof. Dr. Victor Voicu;
-Lector sub egida European Addiction Training Institute, Amsterdam : « New
approaches in Drug and Alcohol Dependence Treatment », 2002
-Invited speaker la 7th Regional Meeting of European College of
Neuropsychopharmacology, 2002
-Membru in Comisia de sustinere a concursului de specialitate, disciplina Psihiatrie,
2002
-Coordonator de centru de studii în cadrul studiului EUFEST (European First Episode
of Schizophrenia) desfăşurat sub egida Uniunii Europene.
-Șef de lucrări, UMF Carol Davila Bucuresti, 2003
-Șef al Secției Psihiatrie din cadrul Spitalului Clinic de Urgenta Militar Central „Carol
Davila”, Bucuresti, iulie 2007
-Absolvent al programului de Master în domeniul Managementului Sistemului de
Sănătate la Universitatea București, cu durata de două semestre (2008);
-Conferențiar universitar Psihofarmacologie Clinica UMF Carol Davila Bucuresti, mai
2009
-Investigator principal și subinvestigator din anul 2000 în studii clinice multicentrice
de fază IIa, IIb, III și IV, axate pe patologii precum schizophrenia, tulburarea schizoafectivă,
tulburarea depresivă majoră, tulburarea afectivă bipolară, demența Alzheimer, demența
fronto-temporală etc.;
2
-Coordonator de formare profesională a rezidenților în specialitatea Psihiatrie în cadrul

Secției Clinice Psihiatrie a Spitalului Universitar de Urgență Militar Central Dr. Carol Davila.
CARȚI PUBLICATE
D. Vasile , M.D. Gheorghe, V. Voicu. Dependenţa de heroină. Editura Medicală Amaltea,

2001; ISBN 973-9397-28-X
D.Vasile. Mit şi realitate în mecanismul dependenţei la benzodiazepine. Editura Medicală

Amaltea Bucureşti, 2003; ISBN 973-9397-59-X.
D. Vasile, O.Vasiliu. Abordări terapeutice cognitiv-comportamentale în cazurile de dublu

diagnostic depresie- tulburări de personalitate. Editura Printech, Bucureşti, 2007; ISBN 978-
973-718-720-8
D.Vasile, O.Vasiliu. Terapia farmacologică a tulburărilor anxioase. Curs. Editura Printech,

Bucureşti, 2008; ISBN 978-606-521-052-3
D.Vasile, O.Vasiliu. Evaluarea şi managementul riscului suicidar în tulburările de

personalitate. Editura Printech, 2008; ISBN 978-606-521-061-5
D.Vasile, O.Vasiliu. Abordări terapeutice în dependenţa de substanţe. Editura Printech, 2009;

ISBN 978-606-521-200-8
D.Vasile, O.Vasiliu. Factori de vulnerabilitate în toxicomanii. Editura Printech, 2009; ISBN

978-606-521-201-5
Cărți publicate de la ultima promovare:
D.Vasile, O.Vasiliu. Psihopatologie generală-vol.1. Semiologie. Editura Printech, 2009; ISBN

978-606-521-356-2
D.Vasile, O.Vasiliu. Psihopatologie generală-vol.2. Sindromologie. Editura Printech, 2009;

ISBN 978-606-521-357-9
D.Vasile, O.Vasiliu. Factorii compliantei terapeutice in psihiatrie. Ed. Printech, 2009; ISBN
978-606-521-370-8
D.Vasile, O.Vasiliu. Psihofarmacologie clinică interactivă. Teste comentate. Ed. Printech,

București, 2013; ISBN 978-606-23-0099-9
CAPITOLE DIN MONOGRAFII
Actualităţi în psihiatria biologică

Editura Intact, 1999.
Coautor la capitolul „Suicidul –o placă turnantă a psihiatriei moderne”
The Role of the Muscarinic Receptors and of the Nitric Oxide in the Morphinic
Withdrawal
Glissando Ed. Iasi, 2001
3
D.Vasile, M.D.Gheorghe In: „Pharmacodependences Mechanism Clinical Aspects,

Treatment”
Semiologie si sindromologie psihiatrica

Editura Universitatii « Carol Davila », 2002
coautor la capitolul « Semiologie psihiatrica orientativa »
Aspecte bioetice ale abordării pacientului în psihooncologie

O.Vasiliu, D.Vasile
în „Standarde europene pentru programe postdoctorale competitive de formare în
domeniul managementului cercetării avansate şi expertizei psihiatrice medico-legale”,
IML Iaşi, Ed.Timpul, Iaşi, 2013
GRANTURI ȘI PROIECTE EDUCAȚIONALE
Proiecte internaționale de cercetare - Central Eastern Europe representative și

responsabil național în următoarele studii clinice:
-A study of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia
(NN25307). Phase 3, 2010.
-A study of RO4917838 in patients with persistent, predominant negative symptoms of
schizophrenia (NN25310). Phase 3, 2010.
Proiecte internaționale de cercetare- responsabil:

-A study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or
related psychotic disorder. Sponsor GW Research LTD. Phase 2 study, placebo controlled.
2013.
-A multicenter, inpatient and ambulatory, phase 2, double-blind, randomized, placebo-
controlled, proof of concept study of CYR-101 in patients with DSM-IV schizophrenia.
Proiecte internaționale de cercetare- membru:

European First Episode of Schizophrenia Trial (EUFEST), 2002-2006
Proiecte educaționale:
Introducere în psihofarmacologie clinică- partea 1, coordonator conf.univ.dr. Daniel Vasile,
24.03.2015, Sponsor Johnson&Johnson
Enseignement postuniversitaire de psychooncologie (coord. Prof.dr. J.Fr. Allilaire si Prof.dr.
I. Popescu)- Bucuresti, 2002- 2003, speaker invitat
Actualități clinice și farmacologice în depresia majoră (4 și 11 noiembrie 2008) organizat de
Liga de Sănătate Mentală, 175 de medici participanți, director de proiect
"New approaches in drug and alcohol addiction" coordinated by European Addiction Training
Institute, lecturer
Granturi de cercetare naționale- membru în echipa de cercetare:

PNCDI II nr.41035/2007 “Evaluarea polimorfismului genetic ca sursă a variabilității
răspunsului terapeutic la medicantele cu metaboliți activi” (POLIGENACT), perioada 2007-
2010
PNCDI II nr.41049/2007 ”Impactul farmacocinetic și clinic al factorilor neuroendocrini în
terapia cu antipsihotice atipice” (HORMONANTIPSI), perioada 2008-2011
4
PNCD II nr.41053/2007 ”Dezvoltarea investigației farmacogenetice pentru personalizarea

terapiei medicamentoase în boala cardiovasculară” (FARMACOGENOMCCV), perioada
2007-2010
CURSURI POSTUNIVERSITARE DE PERFECȚIONARE ÎN ȚARĂ:
1. U.M.F. « Carol Davila » Bucuresti ; specializarea Neurologie- Urgențe neurologice :

diagnostic clinic si tratament, 1998
2. U.M.F. « Carol Davila » Bucuresti ; specializarea Psihiatrie-Urgențe psihiatrice :
diagnostic clinic si tratament, 1998
3. Centrul de Perfectionare Postuniversitara a Medicilor si Farmaciștilor- S.M.C.
Bucuresti- : Strategii terapeutice actuale in practica psihiatrica, 1999
4. Centrul de Perfectionare Postuniversitara a Medicilor si Farmacistilor- S.M.C.
Bucuresti-Introducere in neurochimia psihiatrica, 1999
5. Centrul de Politici si Servicii de Sanatate, in colaborare cu Open Society Institute New
York- Sinaia- : « Implementing Effective Drug Substitution Therapy in
Romania »,2000
6. Enseignement postuniversitaire de psychooncologie (coord. Prof.dr. J.Fr. Allilaire si
Prof.dr. I. Popescu)- Bucuresti, 2002- 2003
7. Managementul sistemului de sănătate. Masterat la Universitatea Bucureşti, Facultatea
de Sociologie şi Asistenţă Socială, 2009
8. Managementul serviciilor de sănătate, Şcoala Naţională de Sănătate Publică şi
Management Sanitar, 2010
9. Standarde europene pentru programe postdoctorale competitive de formare în
domeniul managementului cercetării avansate şi expertizei psihiatrice medico-legale”,
program desfăşurat de Centrul de Cercetare Avansată Bucureşti, în perioada ianuarie-
iunie 2011
10. Standarde europene pentru programe postdoctorale competitive de formare în
domeniul managementului cercetării avansate şi expertizei psihiatrice medico-legale,
program desfăşurat de Centrul de Cercetare Avansată Iasi, în perioada aprilie 2012-
aprilie 2013.
CURSURI POSTUNIVERSITARE DE PERFECȚIONARE ÎN

STRĂINĂTATE :
1. Reseau Ville- Hopital Toxicomanies de Lyon, France : Stage complete sur le dispositif
specifique de prise en charge des personnes presentant une pharmacodependance, 2000
2. Centre Hộspitalier Universitaire Brugmann, Bruxelles, Belgium-Stage dans la Clinique d’
Alcoologie et des Toxicomanies, 2000
3. Centre Medical Enaden, Bruxelles, Belgium-Toxicomanies- Alcool, drogues,
Medicaments, 2000
4. European Addiction Training Institute- Antwerp, Belgium : « Techniques of Relapse
Prevention of Addictive Behaviours », 2001
5. Hộspital Erasme, Bruxelles, Belgium- Stage de formation dans le service de psychiatrie et
au Laboratoire du sommeil conduit par le Professeur Julien Mendlewicz,2001
6. Jellinek Centre and the European Addiction Training Institute, Amsterdam, Holland :
Program with experts of the Jellinek, 2001
7. Université Libre de Bruxelles- Centre Hospitalier Universitaire Brugmann, Bruxelles,
Belgium-Psychoses et troubles de l’humeur, 2001
5
8. Institut de Psychiatrie et de Psychologie Medicale Bruxelles, Belgium: Techniques

d’electrophysiologie diagnostique adaptée aux patients psychiatriques, 2001
9. Unitas de conduitas addictivas, Valencia, Espana : Los tratamientos para los addictivos,
2002
10. Hospital Universitario de San Juan, Alicante, Espana : Programa DRAO en el Servicio de
Medicina Intensiva, 2002
CERCETĂRI FARMACOCLINICE (selectiv)
Investigator principal în următoarele studii multicentrice internaționale:
1. European First Episode of Schizophrenia Trial (EUFEST), 2002-2006

2. RIS-SCP-402 Safety Risperidone vs Quetiapine vs placebo in patients with acute
exacerbation of schizophrenia or schizo-affective disorders, 2004;
3. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and
safety of asenapine compared to placebo using haloperidol positive control in subjects with an
acute exacerbation of schizophrenia, Phase III, 2005-2006, Principal Investigator.
4. A multicenter, double-blind, flexible-dose, long-term extension trial of the safety and
maintenance of effect of asenapine using a haloperidol positive control in subjects who
complete protocol 041023, Phase III, 2006-2007, Principal Investigator.
5. A randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate
the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with
Schizoaffective Disorder, Phase III, 2007-2008, Principal Investigator.
6. An open-label, multi-center, 6-week, sequential cohort study designated to determine
the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic
schizophrenia or schizo-affective disorder, Phase IIa, 2007-2008, Principal Investigator.
7. A six-week, randomized, double-blind, placebo controlled, parallel, multicenter, IIb
phase study to determine the efficacy, safety, and tolerance of non-overlapping low and high
doses of BL-1020 versus placebo and risperidone in patients with acute exacerbations of
schizophrenia, 2008-2009, Principal Investigator.
8. A multicenter, Inpatient and ambulatory, Phase 2, Double-blind, Randomised,
Placebo-controlled, Proof of Concept Study of CYR-101 in Patients with DSM-IV
Schizophrenia, 2008-2009, National Coordinator.
9. A Multinational, randomized, double-blind, placebo-controlled, dose ranging study to
assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder.
Protocol Lu AA21004/CCT-002. 2010. Principal Investigator.
10. Interventiona, randomized, double-blind, parallel-group, placebo-controlled, flexible-
dose long-term study to evaluate the maintenance efficacy and safety of 1 to 3 mg/day of
brexpiprazole as adjunctive treatment in patients with major depressive disorder with an
inadequate response to antidepressant treatment. Protocol 14570A, 2013.
11. Effects of F17464 in acute exacerbation of schizophrenia. Protocol F17464 GE 2 01.
2014.
12. A randomized, double-blind, placebo-controlled, parallel, 24-week, adaptive design
phase 2 study of three different doses of an alpha-7 nicotinic acetylcholine receptor agonist
(EVP-6124) or placebo in subjects with mild to moderate probable Alzheimer’s disease.
13. A randomized, placebo-controlled, double-blind study of LY2216684 flexible-dose 12
mg to 18 mg once daily and LY2216684 fixed-dose 6 mg once daily as adjunctive treatment
for patients with major depressive disorder who are partial responders to selective serotonin
reuptake inhibitor treatment. Protocol H9P-MC-LNBQ, 2010.
6
14. A randomized, double-blind, placebo-controlled, parallel-group, comparative,

multicenter, phase 2 clinical study to evaluate efficacy and safety of two doses of LND101001
monotherapy in patients with mild to moderate Alzheimer’s disease. Protocol
LRP/LND101001/2013/001. 2015.
15. A phase 2, multicenter, open-label study to assess the safety and tolerability of oral
OPC-34712 as monotherapy in adult patients with schizophrenia, 2010. Protocol 331-08-210.
16. A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of three
fixed doses of OPC-34712 in the treatment of adults with acute schizophrenia, 2011, protocol
331-10-231.
17. A study of GWP42003 as adjunctive therapy in the first line treatment of
schizophrenia or related psychotic disorder. Sponsor GW Research LTD. Phase II study,
placebo controlled. 2013. -Efficacy and safety of tianeptine oral administration (25 to 50
mg/day) in elderly patients suffering from Major Depressive Disorder. National coordinator.
18. A 8-week, randomized, double-blind, flexible-dose, parallel groups, placebo-
controlled, international, multicenter study with escitalopram as active control, followed by an
optional double-blind extension treatment period of 16 weeks. Protocol CL3-01574-237.
2013.
19. A randomized, double-blind, placebo-controlled, parallel-group study of Paliperidone
Palmitate evaluating time to relapse in subjects with schizoaffective disorder. Phase III, 2010.
20. A randomized, double-blind, placebo-controlled study to evaluate the efficacy and
safety of low-dose lurasidone in acutely psychotic subjects with schizophrenia. Protocol
D1050303. Phase III, 2013.
21. A 52-week, multicenter, open-label, study to evaluate the effectiveness of an
intramuscular depot formulation of aripiprazole (OPC-14597) as maintenance treatment in
patients with bipolar I disorder. Protocol 31-08-252. Phase III, 2012.
22. A 52-week, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of
aripiprazole (OPC-14597) as maintenance treatment in patients with bipolar I disorder.
Protocol 31-08-250. Phase III, 2013.
23. Randomized, double-blind, placebo-controlled, parallel-group, 12-month trial of
leuco-methylthioninium bis(hydromethanesulfonate) in subjects with mild to moderate
Alzheimer’s Disease. Protocol Trx-237-015. Phase II. 2012.
24. ADAMANT- A 24-months randomized, placebo-controlled, parallel-group, double
blinded, multicenter, phase 2 study to assess safety and efficacy of AADvac1 applied to
patients with mild Alzheimer’s disease. Phase II. 2016.
25. Early effect of agomelatine on general interest in outpatients in Major Depression
Disorder. A 12-week, randomized, double-blind, multicenter study with parallel groups:
agomelatine (25 mg/day given orally with blinded potential adjustment to 50 mg/day) versus
escitalopram (10 mg/day given orally with blinded potential adjustment to 20 mg/day).
Protocol CL3-20098-083. 2011.
26. A study of RO4917838 in patients with sub-optimally controlled symptoms of
schizophrenia (NN25307). Phase III, 2010. National Coordinator, Central Eastern Europe
representative.
27. A study of RO4917838 in patients with persistent, predominant negative symptoms of
schizophrenia (NN25310). Phase III, 2010. National Coordinator, Central Eastern Europe
representative.
28. A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy
and safety of once a day, TAK-375 (Ramelteon) tablet for sublingual administration (TAK-
375SL tablet) 0.1 mg and 0.4 mg as an adjunctive therapy in the treatment of acute depressive
7
episodes associated with bipolar 1 disorder in adults subjects. Protocol TAK-375SL_301.

2012.
29. A multicenter, randomized, double-blind study to evaluate the efficacy, safety and
tolerability of an oral aripiprazole/escitalopram combination therapy in patients with major
depressive disorder. Protocol 31-08-256, 2010.
30. Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients
with Alzheimer’s disease: a randomized, double-blind, placebo-controlled, parallel-group,
multicentre study of 12 weeks. Protocol 3098006, 2010.
PARTICIPĂRI LA MANIFESTĂRI ȘTIINȚIFICE NAȚIONALE ȘI

INTERNAȚIONALE
1. 17 th Danube Symposium of Psychiatry, Timişoara-Romania, 24-27 Aprilie, 1996

2. 1st Congress of Balkan Military Medical Committee, Istanbul-Turcia, 6-8 Mai, 1996
3. International Conference on Suicide: Biopsychosocial Approaches Atena-Grecia,
16-19 Mai, 1996
4. IVth Salon International Psy & SNC, Paris-Franţa, 15-19 Octombrie, 1996
5. 2nd Congress of the Balkan Military Medical Committee, Sofia-Bulgaria, 6-9
Octombrie, 1997
6. 4th Congress of the Balkan Military Medical Committee Bucarest, 6-9 June, 1999
7. XXth Congress of the International Association for Suicide Prevention, 6-10 Nov.,
Athens-Greece,1999
8. 5th Congress of Balkan Military Medical Comitee, Ankara-Turkey, 25-28 Sept.,
2000
9. Implementing Effective Drug Substitution Therapy in Romania, 18-21 sept. 2000
Sinaia, simpozion organizat de Open Society Institute New York and Center for Health
Policies and Services
10. 10 th Association of European Psychiatrists Congress, Praga 28 Oct-1 Nov, 2000
11. Alzheimer Europe 11th Conference June 10-12, 2001, Bucharest, Romania
12. 7th World Congress Biological Psychiatry 1-6 July 2001 Berlin, Germany
13. 7th Regional Meeting of European College of Neuropsychopharmacology,
Bucharest,19-21 Aprilie 2002
14. 5th Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries,
Constanta, 29mai-01iun.2002
15. 3th Regional Meeting: Financing Mintal and Addictive Disorders in Central and
Eastern Europe, Bucharest, 23-25.11.2001
16. 15th Congress of the European College of Neuropsychopharmacology, Barcelona,
Spain, October 5-9, 2002
17. 3rd Conference of International Early Psychosis Association, Copenhagen,
Denmark, 24-28 September, 2002.
18. „Global Adivsory Forum – Risperdal Consta”, Cannes - Franţa, 9-10 November,
2003
19. AEP Spring Symposium „Memories”, Roma - Italia, 24 –26 april, 2003
21. 8th Congress of BMMC, Cluj,2003
22. Forumul de psihiatrie, 2004.
23. 12th WPA International Congress, Florenta, nov. 2004
24. 17th ECNP Congress, Stockholm, oct.2004
25. International Congress of Biological Psychiatry, Sydney, feb. 2004
26. Conferinta Nationala de Terapie si Management in Psihiatrie, sept.-oct. 2004,
Craiova
8
27. Forumul de Psihiatrie 2005

28. 8th World Congress of Biological Psychiatry,Vienna, jul 2005
29. 13 th WPA International Congress, Cairo, 10-15 sept 2005
30. Students and Young Doctors 1st European Congress of Military Medicine,
Bucharest, oct. 2005
31. 18th ECNP Congress, Amsterdam, 22-26 oct. 2005
32. 11th Congress of Balcan Military Committee, Athens, june 18-22, 2006
33. 19th ECNP Congress, 16-20 sep 2006, Paris
34. 15th European Congress of Psychiatry, Madrid, Spain, March 17-21, 2007.
35. American Psychiatric Association 160th Annual Meeting „Addressing Patient
Needs: Access, Parity and Human Care”, San Diego, may 19-24, 2007
36. 39th International Danube Symposium for Neurological Sciences and Continuing
Education in conjunction with the 1st International Congress on ADHD from childhood to
adult disease, 2-5 june 2007, Wurzburg
37. Forumul de Psihiatrie 2007, Bucuresti, 21-23 iunie 2007
38. '8th International Psychiatry Forum - Mind Matters Organised by sanofi-aventis'
Bucharest, 22-23 June 2007 Bucharest.
39. 12th Congress of BMMC, 24-28 iunie 2007, Poiana Brasov
40. The 20th ECNP Congress, 13-17 oct 2007, Vienna, Austria
41. Astra Zeneca Neuroscience Academy 16-18 nov 2007, Bruxelles
42. An international meeting of minds supported by AstraZeneca Meet-the-Expert
Workshop, 3-5 March 2008 Athens, Greece
43. American Psychiatric Association 161st Annual Meeting, Washington, 03-08 may
2008
44. 13th Congress of BMMC, 1-5 june 2008, Kusadasi
45. XXVI CINP Congress, 13-17 july, Munich, Germany
46. 12th EFNS Congress, Madrid, Spain, 23-26 aug, 2008
47. 21’st Congress of the European College of Neuropsychopharmacology, 30 aug –
03 sep 2008, Barcelona, Spain
48. XIV World Congress of Psychiatry, 20-25 sep 2008, Praga
49. „Living with bipolar disorder: symptom control and beyond” – an international
meeting of minds sponsored by AstraZeneca Neuroscience, 27-29april 2009, Stockholm,
Suedia
50. American Psychiatric Association 162nd Annual Meeting, „Shaping our future:
science and service”, San Francisco 16-21 may 2009
51. 9th World Congress of Biological Psychiatry, 28 june-2 july 2009, Paris, France.
52. Simpozionul regional „Optiuni terapeutice actuale in tratamentul schizofreniei si al
depresiei”, Bucuresti, 10, 16 iulie 2009
53. „Preceptorship Programme on Alzheimer’s Disease”, Alzheimer Center at the VU
University Medical Center, 6 nov 2009 Amsterdam, Netherlands
54. 23rd ECNP Congress, 28 August-01 September 2010, Amsterdam, Netherlands
55. Recent Advances in Risk Management, Assessment and Mitigation, 2010,
București
56. 19th European Congress of Psychiatry, 12-15 March, Vienna, Austria
57. 26th ECNP Congress, 5-9 October 2013, Barcelona, Spain
58. 21st European Congress of Psychiatry, 6-9 April 2013, Nice, France
59. 27th ECNP Congress, 18-21 October 2014, Berlin, Germany
60. 23rd European Congress of Psychiatry, 28-31 March 2015, Vienna, Austria
61. 24th European Congress of Psychiatry, 12-15 March 2016, Madrid, Spain
62. 29th ECNP Congress, 17-20 September 2016, Vienna, Austria
9
LUCRĂRI IN-EXTENSO COTATE ISI
1. Vasile D, Vasiliu O. Management of affective symptoms and quality of life improvement

after primary brain tumor surgery. North Atlantic University Union Proceedings of the World
Medical Conference, 2010, 276-278
2. D.Vasile. Harm-reduction as risk decreasing strategy in heroin dependence. North Atlantic

University Union Proceedings of the World Medical Conference, 2010, 294-296.
3. Vasile D, Vasiliu O. Anticonvulsants for severe behavioral disturbances in Alzheimer

dementia. North Atlantic University Union Proceedings of the World Medical Conference,
2010, 279-283
4. Vasile D, Vasiliu O. Management of Cognitive symptoms in dementia associated with

Parkinson’s disease. North Atlantic University Union Proceedings of the World Medical
Conference, 2010, 284-286
5. Vasile D, Vasiliu O. Matching Psychotropics to Neurobiological Mechanisms in the

Aftermath of a Traumatic Event: A Literature Review. North Atlantic University Union
Proceedings of the World Medical Conference, 2010, 287-293.
6. Landolt K, Rossler W, Ajdacic-Gross V, Derks EM, Libiger J, Kahn RS, Fleischhacker

WW, EUFEST Study Group (Vasile D et al). Predictors of discontinuation of antipsychotic
medication and subsequent outcomes in the European First Episode Schizophrenia Trials
(EUFEST). Schizophr Res 2016;172(1-3):145-51. doi:10.1016/j.schres.2016.01.046.
7. Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, Fleishhacker WW, Kahn RS,

Peuskens J, EUFEST Study Group (Vasile D et al). Extrapyramidal symptoms during
treatment of first schizophrenia episode. Eur Neuropsychopharmacol 2014;24(9):1500-5.
doi:10.1016/j.euroneuro.2014.07.001.
8. Riecher-Rossler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS, Malik P,

Fleischhacker WW, EUFEST Study Group (Vasile D et al). Hyperprolactinemia in
antipsychotic-naïve patients with first-episode psychosis. Psychol Med 2013;43(12):2571-82.
doi:10.1017/S0033291713000226.
9. Wobrock T, Falkai P, Schmeider-Axmann T, Hasan A, Galderisi S, Davidson M, Kahn RS,

Derks EM, Boter H, Rybakowski JK, Libiger J, Dollfus S, Lopez-Ibor JJ, Peuskens J, Hranov
LG, Gaebel W, Fleischhacker WW, EUFEST study group (Vasile D et al). Comorbid
substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in
the EUFEST study. Schizophr Res 2013; 147(1):132-9. doi:10.1016/j.schres.2013.03.001.
10. Czobor P, Volavka J, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW,
EUFEST Study group (Vasile D et al). Insight and hostility as predictors and correlates of
non-adherence in the European First Episode Schizophrenia Trial. J Clin Psychopharmacol
2013; 33(2):258-61. Doi:10.1097/JCP.0b013e3182856886.
11. Fleischhacker WW, Siu CO, Boden R, Pappadopulos E, Karayal ON, Kahn RS, EUFEST
Study Group (Vasile D et al). Metabolic risk factors in first-episode schizophrenia: baseline
10
prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J
Neuropsychopharmacol 2013;16(5):987-95. doi: 10.1017/S1461145712001241.
12. Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS, EUFEST
Study Group (Vasile D et al). Persistent negative symptoms in first episode with
schizophrenia: results from the European First Episode Schizophrenia Trial. Eur
Neuropsychopharmacol 2013;23(3):196-204. doi: 10.1016/j.euroneuro.2012.04.019.
13. Rybakowski JK, Vansteelandt K, Szafranski T, Thys E, Jarema M, Wolfgang

Fleishhacker W, Kahn RS, Peuskens J, EUFEST Study Group (Vasile D et al). Treatment of
depression in first episode of schizophrenia: results from EUFEST. Eur
Neuropsychopharmacol 2012;22(12):875-82. doi:10.1016/j.euroneuro.2012.04.001.
14. Landolt K, Rossler W, Burns T, Ajdacic-Gross V, Galderisi S, Libiger J, Naber D, Derks

EM, Kahn RS, Fleischhacker WW, EUFEST Study Group (Vasile D et al). Unmet needs in
patients with first-episode schizophrenia: a longitudinal perspective. Psychol Med
2012;42(7):1461-73. doi:10.1017/S0033291711002406.
15. Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW,
EUFEST Study Group (Vasile D et al). Efficacy of antipsychotic drugs against hostility in the
European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry 2011;72(7):995-61.
doi:10.4088/JCP.10m06529.
16. Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW,

EUFEST Study Group (Vasile D et al). Sexual dysfunction in first-episode schizophrenia
patients results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol
2011;31(3):274-80. Doi:10.1097/JCP.0b013e3182199bcc.
17. Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS, EUFEST Study Group
(Vasile D et al). antipsychotic drug treatment in first-episode psychosis: should patients be
switched to a different antipsychotic drug after 2,4 or 6 weeks of non-response? J Clin
Psychopharmacol 2010;30(2):176-80. doi: 10.1097/JCP.0b013e3181d2193c. 25 citări
18. Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, Rossler W,
Fleischhacker WW, EUFEST Study Group (Vasile D et al). Drug attitude as predictor for
effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).
Eur Neuropsychopharmacol 2010;20(5):310-6. doi:10.1016/j.euroneuro.2010.02.001.
19. Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS, EUFEST Study Group
(Vasile D et al). Generalizability of the results of efficacy trials in first-episode schizophrenia:
comparison between subgroups of participants of the European First Episode Schizophrenia
Trial (EUFEST). J Clin Psychiatry 2010;71(1):58-65. doi:10.4088/JCP.08m04506yel.
20. Boter H, Peuskens J, libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS,
EUFEST Study Group (Vasile D et al). Effectiveness of antipsychotics in first-episode
schizophrenia and schizophreniform disorder on response and remission: an open randomized
clinical trial (EUFEST). Schziophr Res 2009;115(2-3):97-103.
doi:10.1016/j.schres.2009.09.019.
11
21. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe
MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov
LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE, EUFEST Study
Group (Vasile D et al). Effectiveness of antipsychotic drugs in first-episode schizophrenia and
schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-
97. doi:10.1016/S0140-6736(08)60486-9.
22. Dima L, Vasile D, Rogozea L, Zia-Ul-Haq M, Bukhari SA, Moga M. Self-perception of

quality of life in patients treated with antipsychotics. Turk J Med Sci 2015;45(4):782-8.
23. Heun R, Ahokas A, Boyer P, Gimenez-Montesinos N, Pontes-Soares F, Olivier V,

Agomelatine Study Group (Vasile D et al). The efficacy of agomelatine in elderly patients
with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry
2013;74(6):587-94. doi:10.4088/JCP.12m08250.
24. Vasile D. Harm-reduction as risk decreasing strategy in heroin dependence. North

Atlantic University Union Proceedings of the World Medical Conference, 2010, 16.
25. Anand R, Geffen Y, Vasile D, Dan I. An open-label tolerability study of BL-1020

antipsychotic: a novel gamma aminobutyric acid ester of perphenazine. Clin
Neuropsychopharmacol 2010;33(6):297-302. Doi: 10.1097/WNF.0b013e3181f8d501.
STUDII PUBLICATE ÎN REZUMAT COTATE ISI
1. Early pharmacological intervention in first episode schizophrenia

Abstracts of the 7th Regional Meeting of ECNP
European Neuropsychopharmacology 2002;12(Suppl.2):S34-S35
Vasile D
2. Reboxetine in the treatment of elderly inpatients with Major Depressive Disorder

European Neuropsychopharmacology 2002;12(Suppl.2):S41
Vasile D, Vasiliu O, Baloescu A, Grigorescu G, Gheorghe MD
3. Efficacy of venlafaxine in the treatment of generalized anxiety disorder

European Neuropsychopharmacology 2002;12(Suppl.2):S56-57
Vasile D, Ciurea R, Baloescu A
4. Efficacy of Rivastigmine on cognitive and behavioural symptoms in patients with

Alzheimer’s disease
Baloescu A, Tudor C, Vasile D, Ciurea R, Gheorghe MD
5. Heroin-consuming relapse after detoxification

Vasile D, Ciurea R, Gheorghe MD
12
6. The efficacy of donepezil in Alzheimer’s disease cognitive deficit

Vasile D, Gheorghe MD
7. The effects of adenosinic agonists and antagonists on behaviour and on EEG activity
in rats
European Neuropsychopharmacoclogy 2002;12(Suppl.3):S438
Cristescu I, Raducanu T, Zugravu A, Vasile D, Stoleru S
8. Antisocial personality disorder-heroin dependence comorbidity

European Neuropsychopharmacoclogy 2002;12(Suppl.3):S392
Vasile D, Gheorghe MD, Ciurea R, Paraschiv S
9. Efficacy of reboxetine and amisulpride on cognitive functions in elderly inpatients

with major depressive disorder and psychotic features
16th Congress of the European College of Neuropsychopharmacology
European Neuropsychopharmacology 2003;13(Suppl.4):S229-230.
Vasile D, Ciurea R, Gheorghe MD
10. Analgesic effect of trazodone in neoplasm associated pain.

European Psychiatry 2004;19 (Suppl.1):233S.
Vasile D, Gheorghe M, Vasiliu O.
11. The efficacy of amisulpride on negative symptoms in chronic schizophrenia.

24th CINP Congress
International Journal of Neuropsychopharmacology 2004;7(Suppl.1):S410.
Vasile D, Gheorghe M, Vasiliu O, Paraschiv SL
12. Side effects of atypical antipsychotics in first episode of schizophrenia in young

males.
4th International Conference on Early Psychosis
Schizophrenia Research 2004;70(1, Supplement):145
Vasile D, Gheorghe MD, Vasiliu O, Apetroaei A, Paraschiv S
13. Clinical course features in first episode schizophrenia in young male.

4th International Conference on Early Psychosis
Schizophrenia Research 2004;70(1, Supplement):113
Vasile D, Gheorghe MD, Vasiliu O, Apetroaei A, Paraschiv S
14. Drug monitoring factors in schizophrenia treatment.

17th ECNP Congress.
Vasile D, Gheorghe M.D, Vasiliu O, Paraschiv S.
13
15. Sexual dysfunctions in patients with depression treated with SSRI: A therapeutic
approach
12th AEP Congress
European Psychiatry 2004;19(Suppl.1):215S
Vasile D, Gheorghe M, Vasiliu O
16. Quality of life assessment in Alzheimer disease

European Psychiatry 2005;20(Suppl.1):S6
Vasile D, Gheorghe M
17. Psychopathological and somatic comorbidity in major depressive disorders.

European Psychiatry 2005;20 (Suppl.1):S147.
Vasile D, Gheorghe M, Vasiliu O, Lungut E
18. The efficacy of bupropion in alcohol dependent patients with major depressive
episode
18th ECNP Congress
European Neuropsychopharmacology 2005;15(Suppl.3):S400.
Vasile D, Gheorghe MD, Vasiliu O
19. Parenteral administration of olanzapine for schizophrenic with agressive behaviour

18th ECNP Congress
Vasile D, Gheorghe MD, Vasiliu O, Baloescu A
20. Antidepressant switch efficacy in SSRI resistant major depressive disorder.

19th ECNP Congress
European Neuropsychopharmacology 2006;16(4):S324
Vasiliu O, Vasile D, Miclos M, Ivanov P
21. Amisulpride association to SSRI in severe major depressive episodes with psychotic
features.
19th ECNP Congress.
Vasiliu O, Vasile D, Paraschiv S, Miclos M, Ivanov P
22. Bupropion efficacy in major depressive disorder and alcohol dependence dual
diagnosis
19th ECNP Congress
Vasile D, Sarmache M, Vasile ML, Gheorghe MD
23. Risperidone long acting im formulation in high risk of noncompliance bipolar

patients
19th ECNP Congress
Vasile D, Vasiliu O, Ojog D, Gheorghe MD
14
24. Negative and cognitive syptomatology improvement during aripiprazole treatment

in chronic schizophrenia
19th ECNP Congress
Gheorghe MD, Voicu VA, Vasile D, Vasiliu O
25. Side effects of atypical antipsychotics – prediction for factor for compliance
19th ECNP Congress
Baloescu A, Vasile D, Gheorghe MD, Grigorescu G
26. Augmenting psychopharmacological treatment with cognitive behavioural therapy

in major depressive disorder with alcohol dependence dual diagnosis. DP-02-02.
39th International Danube Symposium for Neurological Sciences and Continuing Education in
conjunction with the 1st International Congress on ADHD from childhood to adult disease, 2-
5 June 2007, Wurzburg.
Journal of Neural Transmission 2007;114(7):CXIX
Vasile D, Vasiliu O, Sarmache M, Terpan M, Ojog D
27. Intramuscular olanzapine efficiency in the accute treatment of schizoaffective

disorder. DP-02-04.
39th International Danube Symposium for Neurological Sciences and Continuing Education in
conjunction with the 1st International Congress on ADHD from childhood to adult disease, 2-
5 June 2007, Wurzburg.
Journal of Neural Transmission 2007;114(7):CXIX
Vasile D, Vasiliu O, Paraschiv S, Vasile M, Brisculescu R.
28. Metabolic adverse events of antipsychotic treatment in chronic schizophrenia

Vasile D, Vasiliu O, Paraschiv S, Ivanov P, Terpan M, Vasile M
29. Venlafaxine XR versus fluoxetine in the treatment of major depressive disorder and
generalized anxiety disorder dual diagnosis
15th AEP Congress
European Psychiatry 2007;22(Suppl.1): S247
Vasile D, Vasiliu O, Ivanov P, Ojog D, Sarmache M, Vasile M
30. Augmenting antidepressant psychopharmacological approach with cognitive-

behavioural therapy in bipolar depression
15th AEP Congress
Vasile D, Vasiliu O, Ojog D, Vasile M, Sarmache M, Terpan M
31. Nonbenzodiazepine versus benzodiazepine hypnotic eficiency in older people

15th AEP Congress
Vasile D, Vasiliu O, Vasile M, Sarmache M, Terpan M
15
32. Intramuscular and orodispersable olanzapine efficiency in the acute treatment of

manic episodes
20th ECNP Congress
Vasile D, Vasiliu O, Paraschiv S, Vasile M, Terpan M
33. Combined atypical antipsychotics and valproate sodium approach in the bipolar I
disorder maintenance treatment
20th ECNP Congress
Vasile D, Vasiliu O, Miclos M, Ivanov P, Sarmache M
34. Combined antidepressants and quetiapine therapy in bipolar depression with

psychotic features- an open label study
20th ECNP Congress
Vasile D, Vasiliu O, Paraschiv S, Ojog D, Vasile M
35. Combined pregabalin and selective serotonin reuptake inhibitors in adjustement

disorders with anxiety
20th ECNP Congress
Vasile D, Vasiliu O, Ivanov P, Sarmache M, Terpan M
36. Alteration of body image perception as a side event of antipsychotic treatment in

schizophrenic patients
16th AEP European Congress of Psychiatry
Vasile D, Vasiliu O, Ivanov P, Terpan M, Paraico I
37. Improving the quality of life in patients with malignant tumors using cognitive
psychotherapy
European Psychiatry 2008;23(Suppl.2):S302-303
Vasile D, Vasiliu O, Vasile M, Sarmache M
38. Coping mechanisms evaluation in chronic schizophrenic patients

Vasile D, Vasiliu O, Vasile M, Terpan M, Paraico I
39. Alzheimer dementia associated cognitive and non-cognitive symptoms evolution

during donepezil treatment
Vasile D, Vasiliu O
40. Cognitive-behavioral therapy efficacy in major depressive disorder and histrionic

personality disorder dual diagnosis
16

Vasile D, Vasiliu O, Ojog D, Brisculescu R, Vasile M
41. Oral risperidone efficacy in Alzheimer dementia with psychotic features

XXVI CINP Congress
The International Journal of Neuropsychopharmacology 2008;11(Suppl.1):176
Vasile D, Vasiliu O, Patriche D, Stanescu B, Bancescu R
42. Bupropion SR augmentation strategy in mirtazapine major depressive disorder

incomplete responders
XXVI CINP Congress
Vasile D, Vasiliu O, Vasile M, Cretu O, Ojog D
43. Serotoninergic combos in treatment resistant depressive disorder

XXVI CINP Congress
Vasile D, Vasiliu O, Vasile M, Cretu O, Terpan M
44. The switch on trazodone in major depressive disorder with significant weight gain
XXVI CINP Congress
Vasile D, Vasiliu O, Vasile M, Cretu O, Ojog D
45. The efficacy of venlafaxine vs. SSRIs in panic disorder and major depressive
disorder dual diagnosis
XXVI CINP Congress
The International Journal of Neuropsychopharmacology 2008;11(Suppl.1):284-285
Vasile D, Vasiliu O, Stanescu B, Bancescu R, Terpan M
46. Efficacy of tianeptine in the treatment of post-stroke depression

12th Congress of the European Federation of Neurological Societies
European Journal of Neurology 2008;15(Suppl.3):267
Vasile D, Vasiliu O, Cretu O, Patriche D, Stanescu B, Bancescu R
47. Therapeutic management of interictal dysphoria in epilepsy

European Journal of Neurology 2008;15(Suppl.3):425
Vasile D, Vasiliu O, Ivanov P, Stanescu B, Terpan M, Bancescu R
48. Atypical antipsychotics in the treatment of non-cognitive symptoms of Alzheimer

dementia
European Journal of Neurology 2008;15(Suppl.3):233-34
Vasile D, Vasiliu O, Ivanov P, Terpan M, Patriche D, Ojog D
49. An open study of the safety and efficacy of a novel antipsychotic (BL-1020) with
reduced risk for extrapyramidal symptoms
21st ECNP Congress
17
Anand R, Davidson M, Geffen Y, Vasile D, Dan I
50. Tolerability of rivastigmine transdermal patch in Alzheimer dementia with psychotic

features
22nd ECNP Congress.
European Neuropsychopharmacology 2009;19:S622-623.
Vasile D, Vasiliu O, Vasile M, Terpan M
51. Efficacy of trazodone in patients diagnosed with generalised anxiety disorder and
benzodiazepine dependence
22nd Congress of ECNP
European Neuropsychopharmacology 2009;19:S617-618
Zavoianu M, Luchian A, Tudor C, Grigorescu G, Vasile D
52. Ziprasidone switching effects on metabolic syndrome in patients treated with others
atypical antipsychotics
22nd Congress of ECNP
European Neuropsychopharmacology 2009;19:S495
Grigorescu R, Voicu V, Vasile D, Grigorescu G, Staicu M
53. Low doses risperidone in cluster A personality disorder- a prospective study.

XXVII CINP Congress
International Journal of Neuropsychopharmacology 2010;13:110
Vasile D, Vasiliu O, Terpan M, Vasile ML, Tudor C, Bogdan V, Mangalagiu AG, Grigorescu
G, Ojog D
54. Galantamine switch in donepezil non-responsive patients with early-onset Alzheimer

dementia
XXVII CINP Congress
Vasile D, Vasiliu O, Tudor C, Vasile ML, Grigorescu G, Bogdan V, Terpan M, Mangalagiu
AG, Petrescu MB, Ojog D.
55. Amisulpride augmentation vs. standard antidepressant therapy in major depressive

disorder.
XXVII CINP Congress.
Grigorescu G, Vasile D, Vasiliu O, Vasile ML, Tudor C, Cantemir A, Zavoianu M,
Mangalagiu AG, Terpan M, Grigorescu R.
56. Quality of life improvement through depression treatment in oncologic patients

18th European Congress of Psychiatry
European Psychiatry 2010;25(Suppl.1):997
Vasile D, Vasiliu O, Vasile ML, Mangalagiu AG, Stanescu B, Petrescu BM, Nastase DM,
Bogdan V
57. The efficacy of psychopharmacologic treatment in depressive disorder associated

with Parkinson’s disease dementia
18
Vasile D, Vasiliu O, Bogdan V, Badescu E, Mangalagiu AG, Stanescu B, Petrescu BM
58. The influence of the conflicting paradigms over the prognosis in major depressive
disorder
Vasile D, Vasiliu O, Vasile ML, Mangalagiu AG, Badescu E, Petrescu BM, Bogdan V, Ojog
D
59. Treatment strategies for the management of the self-agressive manifestations in

heroin dependence
Vasile D, Vasiliu O, Vasile ML, Mangalagiu AG, Stanescu B, Terpan M, Nastase DM,
Petrescu BM, Bogdan V
60. Addressing self-image distorsions as a core feature in the alcohol dependence

psychotherapeutic approach
European Psychiatry 2010;25(Suppl.1):1678.
Vasile D, Vasiliu O, Mangalagiu AG, Vasile ML, Badescu E, Bogdan V, Terpan M, Ojog
DG, Petrescu BM
61. Efficacy of milnacipran in patients with interferon-a2 induced depression

23rd Congress of ECNP
Zavoianu M, Cantemir A, Tudor C, Grigorescu G, Vasile D.
62. Influences between defense mechanisms and antidepressants on the therapeutic

compliance in major depressive disorder
23rd ECNP Congress
European Neuropsychopharmacology 2010;20:S343-S344
Vasile D, Vasiliu O, Vasile ML, Terpan M, Mangalagiu A, Bogdan V, Ojog D, Petrescu MB,
Paraico I
63. Comparative efficacy of cholinesterase inhibitors in dementia associated with

Parkinson’s disease
23rd ECNP Congress
Vasile D, Vasiliu O, Vasile ML, Terpan M, Grigorescu G, Bogdan V, Mangalagiu A,
Petrescu MB, Ojog D.
64. Standard antidepressant therapy vs association between amisulpride and

antidepressant theray in atypical depression
23rd ECNP Congress
Grigorescu G, Baloescu A, Vasile D, Tudor C, Vasiliu O, Grigorescu R
19
65. Agomelatine versus selective serotoninergic reuptake inhibitors in major depressive

disorder and comorbid diabetes mellitus.
24th Congress Meeting of ECNP
Vasile D, Vasiliu O, Vasile M.L, Terpan M, Ojog DG
European Neuropsychopharmacology 2011;21(Suppl.3):S383-384.
66. Efficacy and safety of duloxetine in patients with melancholic depression

24th Congress Meeting of ECNP
Tudor C, Cantemir A, Grigorescu G, Vasiliu O, Vasile D, Zavoianu M.
67. Cognitive behavioral therapy focused upon communicational skills enhancement in

anorexia nervosa- a case series
European Psychiatry 2011;26 (Suppl.1):P02-144
Vasile D, Vasiliu O, Mangalagiu AG, Tudor C, Bogdan V, Paraico I
68. Valproate and cognitive therapy combined treatment efficacy in pathological

gambling
European Psychiatry 2011;26(Suppl.1):P03-121
Vasile D, Vasiliu O, Vasile B, Tudor C, Mangalagiu AG, Ojog DG
69. Therapeutic efficacy of duloxetine versus selective serotonin reuptake inhibitors in

irritable bowel syndrome
Vasile D, Vasiliu O, Tudor C, Bogdan V, Mangalagiu AG, Vasile ML, Terpan M
70. Incidence of axis I and II dual diagnosis in hospitalized patients with somatization
disorder
Vasile D, Vasiliu O, Grigorescu G, Mangalagiu AG, Ojog DG, Bogdan V
71. Naltrexone efficacy in alcohol dependence with comorbid axis II diagnosis

European Psychiatry 2012;27(Suppl.1):P-101
Vasile D, Vasiliu O, Mangalagiu AG, Banica A, Stanescu B, Blandu M
72. Comparative analysis of dual serotonergic and noradrenergic antidepressants in

double depression with alcohol dependence
Vasile D, Vasiliu O, Mangalagiu AG, Banica A, Taina NF, Blandu M
73. Quality of life assessment in colon malignant tumors associated depression during
trazodone treatment
Vasile D, Vasiliu O, Mangalagiu AG, Blandu M, Banica A
20
74. Improvement of prognosis through long acting risperidone versus combined

adherence focused psychotherapy and oral antipsychotics in chronic schizophrenia.
Vasile D, Vasiliu O, Mangalagiu AG, Banica A, Taina NF, Stanescu B
75. Comparative analysis of agomelatine and trazodone in late-onset major depression

26th ECNP Congress
D.Vasile, O.Vasiliu, C.Tudor, A.G. Mangalagiu, O.Magazin, G.A. Sopterean, R.E. Bratu
76. Pharmacological management of affective symptoms after primary hepatic tumor

surgery
International Journal of Neuropsychopharmacology 2012;15(Suppl.1):P-14-062
Vasile D, Vasiliu O, Mangalagiu AG, Nanca A
77. Comparative efficacy of cholinesterase inhibitors in dementia associated with

Vasile D, Vasiliu O, Mangalagiu AG, Blandu M, Nanca A
78. Quality of life assessment in fibromyalgia during duloxetine treatment

Vasile D, Vasiliu O, Mangalagiu AG, Blandu M, Nanca A
79. Naltrexone effectiveness in alcohol dependence with comorbid cluster B personality

disorders
Vasile D, Vasiliu O, Blandu M, Ojog DG
80. A multicentric, retrospective data collection from patients diagnosed with

schizophrenia switched to amisulpride- SWITCH study
26th ECNP Congress
D.Vasile, R.A. Macovei, O.Vasiliu, D.Ojog.
81. Evolution of addictive comorbidities in a group of patients diagnosed with

schizophrenia during atypical antipsychotic treatment
21st European Congress of Psychiatry
European Psychiatry 2013;28(1):1127
Vasile D, Macovei RA, Vasiliu O, Mangalagiu AG, Tudor C
82. The efficacy of social skills training over self-image distorsions in avoidant
personality disorder
Vasile D, Vasiliu O, Mangalagiu AG, Blandu M, Magazin O
83. Characteristics of the antipsychotic switch to amisulpride in schizophrenia in

Romanian practice- a multicentric, retrospective data collection (SWITCH study)
21

Vasile D, Vasiliu O, Mangalagiu AG, Petrescu BM
84. A multicentric, retrospective data collection from patients diagnosed with

schizophrenia switched to Solian ® in Romanian practice- SWITCH study
21st European Congress of Psychiatry.
Vasile D, Vasiliu O, Mangalagiu AG, Petrescu BM
85. Mirtazapine versus sertraline in the treatment of post-psychotic depression

26th ECNP Congress
Vasile D, Vasiliu O, Sopterean GA, Bratu RE
86. Efficacy and tolerability of bupropion in major depressive disorder associated with
26th ECNP Congress
Vasile D, Macovei RA, Vasiliu O
87. Pharmacological management of alcohol dependence in chronic schizophrenia

26th ECNP Congress
Vasile D, Vasiliu O, Tudor C, Mangalagiu AG, Petrescu BM, Sopterean GA, Bratu RE
88. Comparative analysis of agomelatine and trazodone in late-onset major depression

26th ECNP Congress
Vasile D, Vasiliu O, Tudor C, Mangalagiu AG, Magazin O, Sopterean GA, Bratu RE
89. Effectiveness and tolerability of nalmefene in alcohol use dependence comorbid with
schizophrenia.
27th ECNP Congress
Vasile D, Vasiliu O, Sopterean GA, Bratu RE, Androne F, Vasile F
90. Pharmacologic treatment strategies in premenstrual dysphoric disorder.

27th ECNP Congress
Vasile D, Macovei RA, Vasiliu O, Vasile F
91. Efficacy and tolerability of agomelatine switch in patients with sexual dysfunctions
treated with serotonin selective reuptake inhibitors
27th ECNP Congress
Vasile D, Macovei RA, Vasiliu O, Vasile F, Ojog DG
92. SSRI dose escalation versus duloxetine in treatment of major depressive disorder not
responding to initial SSRI
27th ECNP Congress
22
European Neuropsychopharmacology 2014;24(2):S455-456.

Petrescu B, Vasile D, Vasiliu O, Tudor C, Mangalagiu A, Ungureanu D
93. Comparative analysis of pregabalin and buspirone as adjunctive agents in major

depressive disorder partially responsive to SSRIs
27th ECNP Congress
European Neuropsychopharmacology 2014;24(2):S389.
Vasile D, Vasiliu O, Bratu RE, Sopterean GA, Vasile F, Ojog DG
94. Analysis of trazodone and pregabalin in neurocognitive disorders with psychomotor

agitation
23rd European Congress of Psychiatry
European Psychiatry 2015;30(Suppl.1):1464.
Vasile D, Vasiliu O, Bratu ER, Sopterean GA, Androne F, Vasile F
95. Affective symptoms as prognosis factor in schizophrenia

23rd European Congress of Psychiatry
Vasile D, Vasiliu O, Vasiliu DG, Vasile F
96. A comparative prospective study of agomelatine versus escitalopram in treatment of

severe major depressive disorder. P.2.f.009.
28th ECNP 2015. European
Neuropsychopharmacology 2015;25(Suppl.2):S439
Petrescu B, Vasile D, Vasiliu O, Mangalagiu AG, Tudor C, Ungureanu D
97. Assessment of suicide risk in schizophrenia with addictive comorbidity. EW567.

Abstracts of the 24th European Congress of Psychiatry
European Psychiatry 2016;33: S315
98. Assessment of sexual dysfunctions in depressive disorder. EV548.

European Psychiatry 2016;33: S525.
99. Assessment of eating disorders in patients diagnosed with major depressive disorder.
EV398.
European Psychiatry 2016;33: S475
100. Therapeutic management of obesity in patients who gained weight during

antidepressant treatment. P.2.h.003.
29th ECNP Congress
Vasile D, Vasiliu O, Bratu-Bazic RE, Androne FT, Patrascu M, Alboae AF, Moraru EA,
Candea C.
23
LUCRĂRI IN-EXTENSO COTATE BDI ȘI CNCSIS
1. Evaluãri multidimensionale prin imagisticã cerebralã în schizofrenie

M.D.Gheorghe, D. Vasile, Arina Baloescu, Gabriela Grigorescu
Revista de Medicinã Militarã, 1996;1:39-47
2. Serotonina - actualitãti în mediatia serotoninergicã - implicatii clinice si terapeutice

M.D.Gheorghe, Arina Baloescu, D. Vasile, R. Mihãitã
Revista de Medicinã Militarã, 1996;2:39-47
3. Interrelatii clinico-paraclinice in schizofrenia negativa

M.D.Gheorghe, D. Vasile, A.Baloescu, G.Grigorescu
Revista de Medicina Militara, 1996;3:243-246
4. Migrena. Actualitati privind fiziopatologia si criteriile de diagnostic

M.D.Gheorghe, E. Lungut, D. Vasile
Revista de Medicina Militara, 1996;4:325-333
5. Schizofrenia-Sindrom pozitiv si negativ (Noi dimensiuni clinico-terapeutice)

M.D.Gheorghe, D.Vasile, A.Baloescu, G.Grigorescu
Medicina Moderna, 1996:III(6):293-295
6. Agenţii antipsihotici atipici – alternativă în tratamentul schizofreniei

D. Vasile
Revista de Toxicologie şi Terapeutică, 3, pg.191, 1998
7. Therapeutical profile in refractory depression

M.D.Gheorghe, D. Vasile, C. Andreescu, Gabriela Grigorescu
Balkan Military Medical Review, 1998;1(2):169-172.
8. Abordări terapeutice în sevrajul la opioide

D. Vasile, M. Stoenescu
Revista Durerea acută şi cronică, 2000;8(2):56
9. Sindromul de sevraj la opiacee. Toxicomania si sarcina

D. Vasile, M. Stoenescu, A.Vasilache
Revista de Medicina Militara, 2001;2 :239
10. Stimularea nervului vag – aplicatii in depresia refractara la tratament

D. Vasile, M.D.Gheorghe, R. Ciurea, C.Tudor
Revista Romana de Psihiatrie, 2001; III(1-2):49-53
11. Tratamentul farmacologic al dependentei de heroina

D. Vasile, M.D. Gheorghe, R. Ciurea, Corina Tudor
Revista Romana de Psihiatrie, 2001; III(3-4):170-174
12. Venlafaxina in tratamentul tulburarii de anxietate generalizata

D. Vasile, R. Ciurea
Revista de Terapeutica, Farmacologie si Toxicologie clinica, 2002;1:136
24
13. O noua abordare terapeutica in durerea cronica: mirtazapina

D. Vasile, M.R.Stoenescu
„Durerea”-Buletin informativ al Asociatiei Romane pentru Studiul Durerii, 2002;XII(1):11-13
14. Comparative Analysis of the Antipsychotics Side Effects in the Onset of

Schizophrenia in Conscripts.
D.Vasile, O.Vasiliu, S.Paraschiv, C.A.Sârbu, M.D.Gheorghe.
Balkan Military Medical Review 2002;5(1-2):24- 30
15. Efectul medicatiei psihotrope asupra intervalului QTc

D.Vasile, O.Vasiliu, S.Paraschiv, E. Lungut, A. Apetroaei
Terapeutică, Farmacologie şi Toxicologie Clinică 2004;VIII(2):115-118
16. Antidepresivele cu mecanism dual versus SSRI in terapia tulburarilor depresive

D.Vasile, M. Gheorghe, O.Vasiliu, A. Apetroaei
Jurnalul Roman de Psihofarmacologie, 2004; 4(1,2):25-31
17. Implicatiile neurobiologice si farmacoclinice ale efectului placebo

D.Vasile, M.Gheorghe, A. Apetroaei, O.Vasiliu
Jurnalul Roman de Psihofarmacologie, 2004; 4(1,2):83-89
18. Factorii deciziei terapeutice- de la experienta clinica la studiile farmacologice

D. Vasile, M.D.Gheorghe, O.Vasiliu, S.Paraschiv
Terapeutică, farmacologie şi toxicologie clinică 2004;VIII(4):63-66
19. Actualitati neurobiologice si farmacoclinice in dementa Alzheimer

D.Vasile, M.D.Gheorghe, O.Vasiliu, A.Apetroaei
Stetoscop 2005;38:42-43
20. Psychotropic Drugs Discontinuation Syndromes in Clinical Practice

D.Vasile, O.Vasiliu, M.Gheorghe, P.Ivanov, D.Ojog
Balkan Military Medical Review 2006;9:38-41
21. Terapia depresiei la pacienţii oncologici

D.Vasile, O.Vasiliu, O.Creţu, B.Stănescu, E.Bădescu, R.Băncescu, M.Terpan
Medicina Modernă 2008; XV(8):407-412
22. Actualităţi şi perspective în terapia farmacologică a tulburărilor de anxietate

D.Vasile, O.Vasiliu, M.Vasile, D.Patriche, A.Bănică
Medicina Modernă 2008; XV(9):488-492
23. Evaluarea profilului terapeutic în adicţii

O.Vasiliu, D.Vasile, N.Mitrofan
Revista de Medicină Militară 2008;2:36-44.
24. Implicaţii clinice ale noilor mijloace de evaluare terapeutică în adicţii

O.Vasiliu, D.Vasile, N.Mitrofan
Revista de Medicină Militară 2008;2:51-61.
25
25. The role of N-Methyl-D-Aspartate receptors in the psychopharmacology of mood

disorders
D.Vasile, O.Vasiliu, M.Vasile, O.Creţu
Therapeutics Pharmacology and Clinical Toxicology 2008; XII(3):349-353.
26. Risperidone long acting administration in type I bipolar disorder noncompliant

patients.
D.Vasile, O.Vasiliu, D.Ojog.
Therapeutics, Pharmacology and Clinical Toxicology 2008; 4(XII):489-492.
27. Perturbările mnezice în tulburările psihice specifice.

D. Vasile, O. Vasiliu.
Revista de Medicină Militară 2008; 1:41-50
28. Evaluarea comorbiditatilor psihiatrice in tulburarile somatoforme

D.Vasile, O.Vasiliu
Revista de Medicină Militară 2008; 2:3-9.
29. Sindroame hepatotoxice asociate medicaţiei psihotrope.

D.Vasile, O.Vasiliu, D. Patriche, B, Stănescu, E. Bădescu, M. Vasile.
Revista de Medicină Modernă 2009;XVI (4):177-181.
30. Rolul axei hipotalamo-hipofizo-corticosuprarenaliene în patogeneza tulburărilor de

anxietate.
D.Vasile, O.Vasiliu.
Revista de Medicină Militară 2009; 2(CXII):35-40
31. Sindroame psihotice induse de agenţii farmacologici psihotropi.

D. Vasile, O.Vasiliu, A.G. Mangalagiu, B.M.Petrescu, B.Stănescu, D.M.Năstase.
Revista de Medicină Militară 2009;3(CXII):33-38
32. Evaluarea mecanismelor defensive la pacientii cu dublu diagnostic- fibromialgie si

tulburare mixta depresiv-anxioasa
D.Vasile, O.Vasiliu, A.G.Mangalagiu, M.L.Vasile, G.Grigorescu, B.Vasile, M.Terpan,
B.M.Petrescu, D.M.Năstase
Revista de Medicină Militară 2010; 2 (CXIII): 43-47
33. Abordari psihofarmacologice ale sistemului melatoninergic in tulburarile hipnice

D.Vasile, O.Vasiliu, A.G.Mangalagiu, D.M.Nastase, B.Vasile, E.Badescu, M.Vasile,
M.Terpan
34. Abordari psihofarmacologice in preventia secundara a stresului posttraumatic

D.Vasile, O.Vasiliu, A.G.Mangalagiu, D.Ungureanu, B.Vasile, M.Vasile, D.M.Nastase
35. Dictionar de psihiatrie- Alogia

D.Vasile, O.Vasiliu
Revista de Medicină Militară 2010;4(CXIII):22
26
36. Cognitive-behavioral therapy efficacy in major depression with associated axis II

risk factor for negative prognosis
D.Vasile, O.Vasiliu
Recent Advances in Risk Management, Assessment and Mitigation, 2010, 460-464
37. Quality of life changes through risk factors reduction focused psychotherapy in
cancer diagnosed patients
D.Vasile, O.Vasiliu, D.G.Ojog
38. Burn-out in a sample of physicians, nurses and medical students- risk factors
analysis
39. Cognitive risk factors for releapse in chronic schizophrenia

D.Vasile, O.Vasiliu, A.G.Mangalagiu
40. Evaluation of the self-aggressive behavior risk factors in oncologic patients

D.Vasile, O.Vasiliu, G.Grigorescu
41. Suicide risk factors assessment in schizophrenia.

D.Vasile, O.Vasiliu, M.Vasile
42. Analiza eficacităţii medicaţiei psihotrope în coşmarurile asociate tulburării de stres

posttraumatic
O.Vasiliu, D.Vasile, NF Taină, AG Mangalagiu, A Bănică
Revista de Medicină Militară 2011; 3 (CXIV): 31-38.
43. Dictionar de psihiatrie- Anhedonia

D.Vasile, O.Vasiliu
Revista de Medicină Militară 2011; 3 (CXIV): 24
44. Evaluation of the mood-stabilizers associated neurocognitive effects in bipolar

patients
D.Vasile, O.Vasiliu, A.G.Mangalagiu, D.G.Ojog,
Therapeutics, Pharmacology and Clinical Toxicology 2011;XV(4):304-308
45. Augmentation strategies in selective serotonin reuptake inhibitors resistant

obsessive-compulsive disorder- a systematic literature review.
D.Vasile, O.Vasiliu, A.G.Mangalagiu, D.G.Ojog.
Therapeutics, Pharmacology and Clinical Toxicology 2011;XV(2):83-92
46. Comparative analysis of dual serotoninergic and noradrenergic antidepressants in

double depression with alcohol dependence
D.Vasile, O.Vasiliu, A.G.Mangalagiu, G.A.Sopterean, R.E.Bratu
Romanian Journal of Psychopharmacology 2013;13(1):7-15
27
47. Comparative analysis of alprazolam, buspirone and pregabalin as add-on agents in

partial responsive generalized anxiety disorder
O.Vasiliu, D.Vasile
Romanian Journal of Psychopharmacology 2015;15(1):26-30.
48. The new wave of atypical antipsychotics- Really new drugs or just another “Me,
Too” drugs?
D.Vasile, O.Vasiliu
49. Analysis of antidepressant drugs impact over quality of life in old-age onset
depressive disorder
O.Vasiliu, D.Vasile, D.G.Vasiliu, F.Vasile
50. Pharmacologic treatment in old-age major depression. A systematic literature review

O.Vasiliu, V.Voicu, D.Vasile
51. Risk factors and quality of life in late-life depressive disorders

O.Vasiliu, D.Vasile
Romanian Journal of Military Medicine 2016;CXIX(3):24-28.
STUDII PUBLICATE ÎN REZUMAT ÎN REVISTE ȘI VOLUME ALE UNOR

MANIFESTĂRI ȘTIINȚIFICE CU ISBN/ISSN
1. Semnificatia psihopatologicã a comportamentului autoagresiv la tineri

Al 17 -lea Simpozion Danubian de Psihiatrie, Timisoara, 24-27 aprilie, 1996
M.D. Gheorghe D. Vasile, Carmen Andreescu, Gabriela Grigorescu, Arina Baloescu, I. Pascu
2. Depresia refractarã conotaţii terapeutice

Al 17 -lea Simpozion Danubian de Psihiatrie, Timisoara, 24-27 aprilie, 1996
M.D. Gheorghe, D. Vasile, Carmen Andreescu, Gabriela Grigorescu
3. Conotatii psihopatologice ale comportamentului autoagresiv la tineri

Congresul National de Toxicologie Clinica, Bucuresti, 13-15.11.1996, Vol. rez. pg.41.
M.D.Gheorghe, D. Vasile, Emilia Lungut, Gh. Clejan
4. Utilizarea Haloperidolului la schizofrenii somalezi – particularitati posologice

Conferinta Nationala de Psihiatrie, Bucuresti, 24-25 oct 1997, vol. rez.p.75
D. Vasile, M.D. Gheorghe, E. Lungut, G. Grigorescu
5. Clinical-Therapeutical Aspects and Encountered with the local Schizophrenic

Patients within the “Restore Hope” Somalia Mission
Congresul de Medicinã Militarã Balcanicã, Sofia, mai 1997, Vol. rez.
D. Vasile, M.D.Gheorghe
28
6. Clinical Features of Khat –intoxication Encountered in the Somali People

3-rd Congress of Balkan Military Medical Committee, Athens, 10-13 May, 416,1998
D. Vasile
7. Alcohol Neurotoxicity: electrophisiology-psychopathology

Emilia Lunguţ, D. Vasile
8. New Therapeuthical Approaches to the First Psychotic Episode in the Soldiers

M.D.Gheorghe, D. Vasile, S.Isacu
9. Serotoninergic Syndrome – a present complication in the psychiatric practice

M.D.Gheorghe, D. Vasile
10. Socio-cultural paricularities of the self-aggressive behaviour in the soldiers

D. Vasile, Gabriela Grigorescu, M.D.Gheorghe
11. Suicidal attempt in the army- romanian experience

20th Congress of the International Association for Suicide Prevention, 6-10 nov 1999, Athens,
Greece, Abstract Book p.125
M.D.Gheorghe, D. Vasile, A. Baloescu, G.Grigorescu
12. New Therapeutical Approaches of Heroin Withdrawal in Polysubstance

Dependence
4th Congress of Balkan Military Medical Committee, Bucharest, June 6-10, Abstract Book,
pg. 191, 1999
Vasile D., M.D.Gheorghe, V.Voicu
13. Restore Hope –Psychiatric Morbidity Structure and Some Peculiarities of Main
Psychopathological Entities, 4th Congress of Balkan Military Medical Committee,
Bucharest, June 6-10, Abstract Book, pg. 235, 1999
Vasile D.
14. Evoked motor responses of the brain, spinal cord and roots – clinical aproach
5th Congress of the Balkan Military Medical Committee Ankara, Turkey 25-28 sept. 2000-
Abstract Book pag. 111
E. Lunguţ, D. Vasile
15. The personality features among heroin withdrawal impatients

5th Congress of the Balkan Military Medical Committee Ankara, Turkey 25-28 sept. 2000-
Abstract Book pag. 144
D. Vasile , M.D. Gheorghe
16. Comportamentul autoagresiv la tineri – caracteristici si management terapeutic

Psihiatria 2000, Congres national cu participare internationala, 4-7 oct 2000, Iasi
29
D. Vasile, M.D. Gheorghe, G. Grigorescu, A. Baloescu
17. Cholinergic therapies used for improving cognitive deficit in Alzheimer disease
Alzheimer Europe 11th Conference 10 – 12th June 2001, Bucharest, Romania
D. Vasile, M.D. Gheorghe
18. Zyprexa in the treatment of behavioral symptoms in dementia

7th World Congress of Biological Psychiatry – 1-6 July 2001 Berlin, Germany- Abstract Book
pag. 123
M.D. Gheorghe, D.Vasile
19. Efficacy and tolerability of Solian in acute exacerbation of schizophrenia

7th World Congress of Biological Psychiatry – 1-6 July 2001 Berlin, Germany- Abstract Book
pag. 301
M.D. Gheorghe, D.Vasile
20. Rolul tomoscintigrafiei cerebrale de perfuzie in diagnosticul dementelor

Primul congres national de medicina nucleara cu participare internationala, Bucuresti, 03-
06.10.2001- Abstract Book, pag.58
Adriana Petrescu, George Marinescu, D. Vasile
21. Fenomenul de recadere in consumul de heroina postsevraj

Conferinta Nationala « Terapie si management in psihiatrie », Craiova, 25-27.10.2001-
Abstract Book, pag.81
D. Vasile, R.Ciurea
22. Electrodiagnosis of diabetic neuropathy (VCM,VCS, F wave and H reflex)

6th Congress of Balkan Military Medical Committee, Plovdiv, Bulgaria, 01-03.10.2001,
Abstract Book, pag.21
E. Lungut, D.Vasile
23. Heroin dependence- personality disorder, a dual diagnosis increasing treatment

costs
Third Regional Meeting, Financing Mental and Addictive Disorders in Central and Eastern
Europe, Bucharest, November 23-25, 2001, Abstract Book, pag.22
D. Vasile, M.D. Gheorghe
24. Abordari terapeutice in dependenta de heroina

5th Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries, Constanta, 29.05-
01.06.2002, Abstract Book, pag.7
D. Vasile
25. Borderline personality- heroin dependence comorbidity

XII World Congress of Psychiatry, 24-29.08.2002, Yokohama, Japan, Abstract Book, pag.38
D. Vasile, M.D.Gheorghe, R. Ciurea
26. The efficacy of donepezil in Alzheimer’s disease cognitive deficit

Abstracts of the 15th Congress of the European College of Neuropsychopharmacology,
Barcelona, Spain, October 5-9, 2002, S374
30
D. Vasile, M.D. Gheorghe.

27. Antisocial personality disorder- heroin dependence comorbidity
Abstracts of the 15 th Congress of the European College of Neuropsychopharmacology,
Barcelona, Spain, October 5-9, 2002 , S392.
D. Vasile, M.D. Gheorghe, R. Ciurea, S. Paraschiv
28. Comparative Analysis of the Antipsychotics Side Effects in the Onset of

Schizophrenia in Conscripts
“Balkan Military Medical Review”, 2002, 5 (1-2):24-29
D.Vasile, O.Vasiliu, S.Paraschiv, C.A.Sirbu, M.D.Gheorghe
29. Imaging contribution in long term monitoring of cerebral hydatosis

“Balkan Military Medical Review”, 2002, 5 (1-2): 63-71
C.A. Sîrbu, D. Vasile, F. Cristea, R. Munteanu, C. Constantin, D. Constantin
30. Utilizarea Exelonului în ameliorarea deficitului cognitiv în Boala Alzheimer

AEP Spring Symposium, Roma , april 24-26, 2003
D.Vasile, R. Ciurea, M.D.Gheorghe
31. The evaluation of personality disorders in soldiers with self-injuring behavior

8th Congress of Balkan Military Medical Committee, Cluj, 2003
O Vasiliu, D. Vasile
32. Trazodone as an optimal treatment for the sexual disfunctions in depressed patients
8th Congress of BMMC, Cluj, 2003
O Vasiliu, D. Vasile
33. Efficacy of the mirtazapine treatment in the neoplasm associated pain

D. Vasile, O Vasiliu
34. Treatment of neoplasm secondary depression using mirtazapine

35. The importance of the family background in heroin-dependence primary and

secondary prophylaxis
36. Weight gain as a secondary effect in typical and atypical antipsychotic treatment of
schizophrenia
37. Cardiovascular side effects caused by the administration of atypical antipsychotics

31
38. The onset of action of mirtazapine in a group of military personnell

39. The efficacy of reboxetine in the treatment of inhibited depression

8th Congress of BMMC Cluj, 2003
40. Noncompliance factors in schizophrenia treatment

9th Congress of BMMC, Antalya, 2004
41. The importance of self image distorsions in depressive disorders with suicidal
attempts
9th Congress of BMMC", Antalya, 2004
42. Defense mechanisms in patients with oncological pathology

O Vasiliu , D. Vasile
43. Sleep quality improvement in depressed patients receiving Trazodone

44. Multiaxial diagnosis and quality of life assessment in Alzheimer disease

D. Vasile, O. Vasiliu
45. Improvement of depressive symptomatology in the onset of schizophrenia

46. Demographic data analysis in heroin dependence patients

47. Correlation between personality features and adjustment disorders in conscripts

48. Trazodone in sexual dysfunctions of depressed patients receiving selective serotonin

reuptake inhibitors
WPA International Congres, Florenta, noiembrie, 2004
32
49. The effect of atypical antipsychotics on depressive symptomatology in schizophrenia

17th ECNP Congress, Stockholm, octombrie, 2004
50. Atypical antipsychotics- Side effects profile

International Congress of Biological Psychiatry, Sydney, 2004
51. Atypical antipsychotics agents in acute psychotic disorder with affective features
The 8th World Congress of Biological Psychiatry, Vienna, Jul 2005
The World Journal of Biological Psychiatry 2005;6(Suppl.1):320
D. Vasile, O.Vasiliu, M. Gheorghe
52. The effectiveness of intravenous Trittico in Major Depresive Episode

The 8th World Congress of Biological Psychiatry, Vienna, Jul 2005
The World Journal of Biological Psychiatry 2005;6(Suppl.1):179
M. Gheorghe, D. Vasile, O.Vasiliu
53. Treatment in Alzheimer dementia with depressed mood

XIII World Congress of Psychiatry, Cairo, September, 10-15, p. 532, 2005
D. Vasile, O. Vasiliu, A. Apetroaei, S. Paraschiv, M.D. Gheorghe
54. Efficacy, safety and compliance in the long acting atypical anipsychotic treatment
XIII World Congress of Psychiatry, Cairo, September, 10-15, p. 716, 2005
M.D.Gheorghe, D. Vasile, G. Grigorescu
55. Bupropion as craving decreasing agent in alcohol dependent patients

11th Congress of Balkan Military Medical Committee, June 18-22, 2006, Athens
Vasile D., Vasiliu O., Gheorghe M.D., Ivanov P., Paraschiv S.
56. Depressive symptomatology cluster analysis

11th Congress of Balkan Military Medical Committee, June 18-22, 2006, Athens
Vasile D., Vasiliu O., Vasile M., Ojog D.
57. Defense mechanism analysis in conscripts diagnosed with adjustment disorders

11th Congress of Balkan Military Medical Committee, June 18-22, 2006, Athens, p. 100
Vasiliu O, Vasile D, Varzaru C, Ojog D.
58. Coping mechanism as prognosis factors in the cognitive behaviour therapy of major
depressive disorder
Vasiliu O, Vasile D, Varzaru C, Ojog D.
59. Psychotherapeutical crisis interventions in depressive disorders with suicidal

ideation
11th Congress of Balkan Military Medical Committee, June 18-22, 2006, Athens, p.33
Vasiliu O, Vasile D, Ivanov P, Paraschiv S.
33
60. Determination of quetiapine in urine samples by GC-MS method

Ionica M, Macovei R, Vasile D, Caragea D, Forje M.
61. Aripiprazole efficacy in chronic schizophrenia with prominent negative symptoms

Vasile D., Vasiliu O, Gheorghe M.D.
62. Augmenting antidepressive psychopharmacological approach with cognitive-

behavioral therapy in refractory major depressive disorder
Vasiliu O, Vasile D, Sarmache M., Vasile M.
63. Psychotropic drugs discontinuation syndromes in clinical practice

Balkan Military Medical Review, 9, January, 38-41, 2006
D. Vasile, O. Vasiliu, M.D.Gheorghe, P. Ivanov, D. Ojog D
64. Nonbenzodiazepine and benzodiazepine hypnotic comparative analysis in organic

conditions secondary insomnia
The Journal of the Association of European Psychiatrists, 14th AEP Congress, Nice, 4-8
march 2006, S152
Vasile D., Vasiliu O., Ojog D., Sarmache M.,Vasile M.,Paraschiv S.
65. Effectiveness of cognitive behavioural therapy in dual diagnosis: panic disorder and
major depressive disorder
march 2006, S152
Vasile D., Vasiliu O., Ivanov P., Paraschiv S.
66. Comorbidity association study in heroin dependent patients

march 2006, S144
Vasile D., Vasiliu O., Ivanov P., Varzaru C., Ojog D., Paraschiv S.
67. Antidepressant switch efficacy in selective serotonin reuptake inhibitors resistant

major depressive disorder
European Neuropsychopharmacology, 19th ECNP Congress Paris, France, 16-20 September,
2006, S324
Vasiliu O, Vasile D, Miclos M, Ivanov P
68. Amisulpride association to selective serotonin reuptake inhibitors in severe major

depressive episodes with psychotic features
European Neuropsychopharmacology, 19th ECNP Congress Paris, France, 16-20 September,
2006, S362
Vasiliu O, Vasile D, Paraschiv S, M. Miclos, Ivanov P.
69. Managementul farmacoterapeutic al pacientilor psihotici agresivi

Terapie si management in psihiatrie, 28 septembrie – 1 octombrie, 2006, Craiova, p.27-28
Vasile D., Vasiliu O, Sarmache M, Vasile M.
34
70. Comorbiditati addictive in tulburarea de panica

Vasiliu O, Vasile D, Ojog D.
71. Evaluarea calitatii vietii la pacientii cu dementa vasculara

Vasile D, Vasiliu O, Varzaru C, Ivanov P.
72. Prim episod schizofrenic – Evaluare SPECT cerebrala de perfuzie pre si post-
tratament cu antipsihotice atipice
Al 2-lea Congres National de Medicina Nucleara 8-11.11.2006, Bucuresti, p.110-111
Rimbu A., Marinescu G, Mititelu R, Ghita S, Mazilu C, Vasile D, Baloescu A, Tudor C,
Isacu S, Vasiliu O, Gheorghe M.D, Codorean I.
73. Compliance Therapy as Increasing Adherence Method for Alcohol Addiction

12th Congress of BMMC, 24-28 iunie 2007, Poiana Brasov
D. Vasile, O.Vasiliu, S.Paraschiv, M. Terpan
74. New methods for mood disorders treatment

75. Ethiological considerations over delirium due to general medical conditions

D. Vasile, O.Vasiliu, M. Vasile, M. Sarmache
76. Comparative analysis of second generation antipsychotics in the treatment of

negative symptoms in chronic schizophrenia
D. Vasile, O. Vasiliu, S. Paraschiv, M. Terpan
77. Bupropion administration in major depressive with alcohol dependence dual

diagnosis
D. Vasile, O.Vasiliu, D. Ojog, M.Terpan
78. Aripiprazole administration in schizoaffective disorder, bipolar type

D. Vasile, O. Vasiliu, M. Sarmache, M. Vasile
79. Anxiety disorders screening in general internal medicine clinic hospitalised patients
D. Vasile, O. Vasiliu, R. Brisculescu, D. Ojog
80. Cognitive behavioural therapy in generalised anxiety disorder

O. Vasiliu, D. Vasile, M. Vasile, M. Sarmache
81. Defense mechanisms analysis in somatoform disorders

35

O. Vasiliu, D. Vasile, R. Brisculescu, D. Ojog
82. Hypothyroidism presenting as psychosis: „mixedema madness” case report

C. Spiroiu, A.E.Ranetti, A. Mazilu, D. Vasile, C.Tudor, O.Vasiliu
83. Cognitive-behavioural therapy and antidepressant drug treatment in irritable bowel

syndrome
Journal of Czech and Slovak Psychiatry, vol.104,suppl.2, XIV World Congress of Psychiatry,
20-25 sep 2008, Prague, p.933
D. Vasile, O. Vasiliu, D. Patriche, P.Ivanov, B. Stanescu
84. The influence of coping mechanisms over the evolution of acute stress disorder
20-25 sep 2008, Prague, p.1145
D. Vasile, O. Vasiliu, M. Vasile, D. Patriche, D. Ojog
85. Crisis therapy intervention in panic disorder

20-25 sep 2008, Prague, p.1235
D. Vasile, O. Vasiliu, M. Vasile, O. Cretu, M. Terpan
86. Guided imagery applications in breast cancer related mixed anxious-depressive

disorder
20-25 sep 2008, Prague, p.1461
D. Vasile, O. Vasiliu, M. Vasile, M. Terpan, D. Ojog
87. The management of alcoholism dependence in patients with oncologic disease

20-25 sep 2008, Prague, p.1461
D. Vasile, O. Vasiliu, O. Cretu, P.Ivanov, B. Stanescu
88. Evaluarea cresterii nivelului de prolactina la pacientii tratati cu antipsihotice atipice.

Al 13-lea Simpozion National de Psihoneuroendocrinologie, Cluj-Napoca, 2006
I. Paul, D. Vasile, O. Vasiliu, A. Raceala
89. Scăderea toleranţei la glucoză la pacienţii cu un prim episod de schizofrenie in

tratament cu antipsihotice atipice
Al 13-lea Simpozion National de Psihoneuroendocrinologie, Cluj-Napoca, 2006
A. Raceala, D. Vasile, O. Vasiliu, P. Ivanov, L. Dumitrache.
90. Provocări etice în psihooncologie

A VII-a Conferinţă Naţională de Bioetică, Bucureşti, 2011
O.Vasiliu, D.Vasile, A.G.Mangalagiu, N.F.Taină, A.Bănică, M.Blându, D.G.Ojog
91. Aspecte etice ale consimţământului informat în cazul pacienţilor cu boala Alzheimer
A VII-a Conferinţă Naţională de Bioetică, Bucureşti, 2011
36
O.Vasiliu, D.Vasile, A.G.Mangalagiu, N.F.Taină, A.Bănică, M.Blându, D.G.Ojog
92. Diagnosticul multiaxial în tulburările somatoforme

Zilele Spitalului Universitar de Urgență Militar Central „Dr.Carol Davila”, 2012, Volum de
rezumate
D.Vasile, O.Vasiliu, AG Mangalagiu, C.Tudor, D.Ungureanu, BM Petrescu, V. Bogdan, G.
Grigorescu, M. Blandu
93. Efficacy of rivastigmine patch in mixed severe neurocognitive disorders

Zilele Spitalului Universitar de Urgență Militar Central “Dr. Carol Davila”, 2014
D.Vasile, O.Vasiliu, M.B.Petrescu.
94. Improving treatment adherence in schizophrenia diagnosed patients by using long

acting injectable antipsychotics
Carol Davila University Central Emergency Military Hospital Scientific Days, 6th Ed.
Romanian Journal of Military Medicine 2016; vol.CXIX(Suppl.):5
O.Vasiliu, D.Vasile, A.G.Mangalagiu, B.M.Petrescu, C.Tudor, C.Candea, R.E. Bazac-Bratu,
F.T.Androne, A.F.Alboaie, M.Patrascu, E.A.Patrascu.
95. Primary prevention in unipolar depression

A.Nistor, T.Hara, C.King, F.Blebea, A.Iftodi, Corina Tudor, O.Vasiliu, D.Vasile
96. Psychiatry and terrorism.

C.Candea, D.Vasile, O.Vasiliu, B.Petrescu, A.Mangalagiu, Irina Candea, A.M.Badic
97. Transcultural psychiatry.

C.Candea, D.Vasile, O.Vasiliu, B.Petrescu, A.Mangalagiu, irina Candea, A.M.Badic.
98. Predictors for treatment response in old age major depressive disorder.
The International Conference “Psychology and the realities of the contemporary world” 7th
Ed., Bucharest.
Romanian Journal of Experimental Applied Psychology, 2016; 7 (Special Issue 2):74
O.Vasiliu, D.G.Vasiliu, D.Vasile.
99. Cognitive behaviour therapy in young patients with alcohol related disorders.
The International Conference “Psychology and the realities of the contemporary world” 7th
Ed., Bucharest.
Romanian Journal of Experimental Applied Psychology, 2016; 7 (Special Issue 2):75
O.Vasiliu, D.G.Vasiliu, D.Vasile.
100. Atipical side effects of antipsychotics – risc factor for noncompliance in first episode
of schizophrenia
37
9th World congress of Biological Psychiatry, The World Journal of Biological Psychiatry,
vol.10-supplement 1-2009, pg.281
R. Grigorescu, V. Voicu, D. Vasile, G. Grigorescu
101. Cognitive impairment profile in schizophrenia. 9th World congress of Biological

Psychiatry.
The World Journal of Biological Psychiatry, 2009;10 (Suppl.1):281-282
G. Grigorescu, D. Vasile, C. Tudor, R. Grigorescu
102. Efficacy of aripiprazole vs. quetiapine for the treatment of hostility in acute
patients with schizophrenia. 9th World congress of Biological Psychiatry.
The World Journal of Biological Psychiatry, 2009;10 (Suppl.1):282.
D. Vasile, G. Grigorescu, C. Tudor, O. Vasiliu, R. Grigorescu
103. Duloxetine versus escitalopram in the treatment of major depressive disorder and
generalized anxiety disorder dual diagnosis. 9th World congress of Biological
Psychiatry.
The World Journal of Biological Psychiatry, 2009;10 (Suppl.1):384
D. Vasile, O. Vasiliu, M. Vasile, G. Grigorescu, M. Terpan
104. Milnacipran efficacy in major depressive disorder and alcohol dependence dual
diagnosis. 9th World congress of Biological Psychiatry.
D.Vasile, O. Vasiliu
105. Tianeptine efficacy in the treatment of multiple sclerosis associated anxiety disorder
9th World congress of Biological Psychiatry.
D. Vasile, V. Voicu.
106. 25 years of fluoxetine: how far are we from an optimal treatment for depression?
Therapeutics, Pharmacology and Clinical Toxicology, 2011;XV(Suppl.II):74
N.F.Taina, D.Vasile, O.Vasiliu, A.G.Mangalagiu, B.Stanescu
107. Nightmare pharmacologic treatment in posttraumatic stress disorder- a systematic

literature review
Therapeutics, Pharmacology and Clinical Toxicology, 2011;XV(Suppl.II):74
N.F.Taina, D.Vasile, O.Vasiliu, A.G.Mangalagiu, A.Banica, D.G.Ojog
108. Analiza eficacitatii terapeutice a duloxetinei comparativ cu inhibitorii selectivi ai

recaptării serotoninei în depresia majoră recurentă cu manifestări atipice
Revista de Medicina Militara 2011; CXIV (Suppl):24
V.Daniel, Vasiliu O, Ungureanu Daniela, Tudor Corina, Bogdan V, Mangalagiu AG, Banica
Anisoara, Grosu Georgeta, Meliaca A
109. Quality of life assessment in patients diagnosed with bipolar disorder and alcohol
dependence
International Clinical Psychopharmacology 2011;26e (Suppl.A): 29
D.Vasile, O.Vasiliu, A.G.Mangalagiu,
38
110. Quetiapine efficacy and tolerability in bipolar II disorder with comorbid cluster C
personality disorder
International Clinical Psychopharmacology 2011;26e (Suppl.A): 29
D.Vasile, O.Vasiliu, G.D.Ojog
111. Familial history of psychotic disorders in patients with bipolar I and II disorder
International Clinical Psychopharmacology 2011;26e (Suppl.A): 29-30
D.Vasile, O.Vasiliu, A.G.Mangalagiu
112. Psychoactive substance induced manic episodes in a population of young patients- a

case series
International Clinical Psychopharmacology 2011;26e (Suppl.A):30
113. Comparative analysis of duloxetine and SSRIs in oncologic patients with major
depressive disorder. P-10-022.
11th World Congress of Biological Psychiatry 2013.
D.Vasile, O.Vasiliu, N.F.Taina, R.Bratu, G.Sopterean.
114. Combined naltrexone and cognitive therapy in binge drinking patients with cluster
B personality features. P-17-014.
D.Vasile, O.Vasiliu, A.G.Mangalagiu, B.M.Petrescu, N.F.Taina.
115. Agomelatine versus escitalopram in the treatment of elderly patients with post-
stroke depression. P-21-016.
D.Vasile, O.Vasiliu, A.G.Mangalagiu, G.Sopterean, R.Bratu, D.G.Ojog.
116. Metabolic profile of long-acting injectable risperidone versus olanzapine pamoate

in chronic schizophrenia. P-24-003.
D.Vasile, O.Vasiliu.
117. The Efficacy of dual action antidepressants in depressive disorder associated with
systematic lupus erythematosus
Romanian Journal of Psychiatry 2013; XV (Suppl.1):P-51
C.Tudor, O.Vasiliu, M.Zavoianu, G.Grigorescu, A.G.Mangalagiu, D.Vasile, O.Magazin
118. Newly diagnosed Alzheimer Dementia cases in non-psychiatric departments of a

general medical hospital- a liaison psychiatry study
Romanian Journal of Psychiatry 2013; XV (Suppl.1):P-69
D. Vasile, O.Vasiliu, A.G.Mangalagiu, M.Blandu, B.M.Petrescu
119. Analysis of the organic comorbidities in early-onset Alzheimer Dementia patients

Romanian Journal of Psychiatry 2013; XV (Suppl.1)
D.Vasile, O.Vasiliu, A.G.Mangalagiu, B.M.Petrescu, M.Blandu
120. Galantamine efficacy and tolerability in amnestic mild cognitive impairment. P-07-
021.
39
11th World Congress of Biological Psychiatry 2013

D.Vasile, O.Vasiliu, A.G.Mangalagiu, G.Sopterean, R.Bratu
121. Efficacy and tolerability of venlafaxine switch in serotonin selective reuptake

inhibitors treated patients with partial response. P-22.
Abstracts of the 12th World Congress of Biological Psychiatry 2015
D.Vasile, O.Vasiliu, D.G.Vasiliu, G.A.Sopterean, R.E.Bratu, F.Androne, F.Vasile
122. Comparative efficacy of bupropion and duloxetine in depressive disorder due to

Parkinson’s disease. P-15.
Abstracts of the 12th World Congress of Biological Psychiatry 2015
D.Vasile, O.Vasiliu, D.G.Vasiliu, F.Androne, F.Vasile
123. Delirium and depression: relationship and clinical overlap in elderly people.
Abstracts of 20th Congress of Balkan Military Medical Committee.
Balkan Military Medical Review 2015;18(5):e77
D.Vasile, B.M.Petrescu, O.Vasiliu, A.Mangalagiu, C.Candea
123. Quality of life assessment in schizophrenia diagnosed patients with predominant

negative symptoms. T273.
5th Schizophrenia Research Society Conference 2016
D.Vasile, O.Vasiliu, D.G.Vasiliu, F.Vasile
124. Pharmacologic management in cases of dual diagnosis- schizophrenia and alcohol

use disorder. M108.
125. Aggressivity management in schizophrenia diagnosed patients using calcium

channel alpha2-delta ligands. S50.
CITĂRI ÎN SISTEM ISI

Lucrările citate:
Anand R, Geffen Y, Vasile D, Dan I. An open-label tolerability study of BL-1020
antipsychotic: a novel gamma aminobutyric acid ester of perphenazine. Clin
Neuropsychopharmacol 2010;33(6):297-302. – 5 citări
Baloescu A, Vasile D,.Gheorghe M.D, Grigorescu G.Side effects of atypical antipsychotics –
prediction for factor for compliance. European Neuropsychopharmacology, 19th ECNP
Congress Paris, France, 16-20 September, 2006, S404 – o citare
D.Vasile, O.Vasiliu, D.Ojog, R. Brisculescu, M. Vasile. Cognitive-behavioral therapy
efficacy in major depressive disorder and histrionic personality disorder dual diagnosis. The
16th AEP European Congress of Psychiatry, Nice, April 5 – 9, 2008 – o citare
Vasile D, Vasiliu O, Vasile M.L, Terpan M, Ojog DG. Agomelatine versus selective
serotoninergic reuptake inhibitors in major depressive disorder and comorbid diabetes
mellitus. 24th Congress Meeting of ECNP, Paris, 2011. European Neuropsychopharmacology
2011;21(Suppl.3):S383-384 – o citare
40
D.Vasile, O.Vasiliu. Management of Cognitive symptoms in dementia associated with

Parkinson’s disease. North Atlantic University Union Proceedings of the World Medical
Conference, 2010, 284-286 – o citare
Grafic 1. Sursa informațiilor: apps.webofknowledge.com, accesat în data de 07/01/2017
D.Vasile, O.Vasiliu, M.Vasile, M.Sarmache. Improving the quality of life in patients with
malignant tumors using cognitive psychotherapy. The 16th AEP European Congress of
Psychiatry, Nice, April 5 – 9, 2008 – o citare
În plus:
D. Vasile, O. Vasiliu, D. Ojog, M.D. Gheorghe. Risperidone long-acting IM formulation in
high risk of non compliance bipolar patients. Proceedings of the 19th ECNP Congress.
European Neuropsychopharmacology 2006;16(4):S413-414
Lucrare citată în Akiskal HS, Tohen M (Eds). Psychopharmacotherapy. Caring for patient. 2 nd
Ed. John Wiley&Sons, Oxford, 2011.
PREMII OBȚINUTE
-ECNP Regional Poster Award: The effects of the adenosinic agonists and antagonists on
behaviour and on EEG activityin rats. I.Cristescu, T.Raducanu, A.Zugravu, D.Vasile,
S.Stoleru. 7th ECNP Regional Meeting 2002, Bucharest, Romania
-11th Congress of Balkan Military Medical Committee Best Poster Presentation Award:
Augmenting Antidepressive Psychopharmacological Approach with Cognitive-Behavioral
Therapy in Refractory Major Depressive Disorder. Vasiliu O, Vasile D, Sarmache M, Vasile
M. 11th Congress of Balkan Military Medical Committee, 2006, Athens, Greece
-Balkan Military Medical Committee: First Prize from Romanian delegation for poster
presentation during 12th Congress of BMMC. 2007, Poiana Brasov, Romania
-13th Congress of Balkan Military Medical Committee: First Prize Poster Award: Psychiatric
Comorbidity in Somatoform Disorders. 2008, Kusadasi, Turkey
41
MEMBRU ÎN ASOCIAȚII PROFESIONALE ȘI ȘTIINȚIFICE
-Secretar General al Balkan Military Medical Committee

-Honorary President of the Balkan Military Medical Committee
-Vicepreședinte al Asociației Medicilor și Farmaciștilor Militari din România
-Membru al Comisiei Interministeriale de Luptă Antidrog
-Membru al European College of Neuropsychopharmacology
-Membru al Association of European Psychiatrists
-Membru al International Early Psychosis Association
ACTIVITATE EDITORIALĂ
-redactor șef adjunct al Revistei de Medicină Militară (2 ani)

-reviewer la European Neuropsychopharmacology (2 ani)

CV DV Dosar

Încărcat de

Informații document

Titlu original

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

CV DV Dosar

Încărcat de

Drepturi de autor:

Formate disponibile

1

DATA NAȘTERII - 29.04.1963

STUDII - Facultatea de Medicină Militară, I.M.F. București, 1987

LIMBI STRĂINE CUNOSCUTE:

-Engleza nivel C1 conform Cadrului Comun European de Referinţă (autoevaluare);

-Medic stagiar in Spitalul Militar Central 1987-1990

-Coordonator de formare profesională a rezidenților în specialitatea Psihiatrie în cadrul

D. Vasile , M.D. Gheorghe, V. Voicu. Dependenţa de heroină. Editura Medicală Amaltea,

D.Vasile. Mit şi realitate în mecanismul dependenţei la benzodiazepine. Editura Medicală

D. Vasile, O.Vasiliu. Abordări terapeutice cognitiv-comportamentale în cazurile de dublu

D.Vasile, O.Vasiliu. Terapia farmacologică a tulburărilor anxioase. Curs. Editura Printech,

D.Vasile, O.Vasiliu. Evaluarea şi managementul riscului suicidar în tulburările de

D.Vasile, O.Vasiliu. Abordări terapeutice în dependenţa de substanţe. Editura Printech, 2009;

D.Vasile, O.Vasiliu. Factori de vulnerabilitate în toxicomanii. Editura Printech, 2009; ISBN

Cărți publicate de la ultima promovare:

D.Vasile, O.Vasiliu. Psihopatologie generală-vol.1. Semiologie. Editura Printech, 2009; ISBN

D.Vasile, O.Vasiliu. Psihopatologie generală-vol.2. Sindromologie. Editura Printech, 2009;

D.Vasile, O.Vasiliu. Psihofarmacologie clinică interactivă. Teste comentate. Ed. Printech,

CAPITOLE DIN MONOGRAFII

Actualităţi în psihiatria biologică

D.Vasile, M.D.Gheorghe In: „Pharmacodependences Mechanism Clinical Aspects,

Semiologie si sindromologie psihiatrica

Aspecte bioetice ale abordării pacientului în psihooncologie

GRANTURI ȘI PROIECTE EDUCAȚIONALE

Proiecte internaționale de cercetare - Central Eastern Europe representative și

Proiecte internaționale de cercetare- responsabil:

Proiecte internaționale de cercetare- membru:

Granturi de cercetare naționale- membru în echipa de cercetare:

PNCD II nr.41053/2007 ”Dezvoltarea investigației farmacogenetice pentru personalizarea

CURSURI POSTUNIVERSITARE DE PERFECȚIONARE ÎN ȚARĂ:

1. U.M.F. « Carol Davila » Bucuresti ; specializarea Neurologie- Urgențe neurologice :

CURSURI POSTUNIVERSITARE DE PERFECȚIONARE ÎN

8. Institut de Psychiatrie et de Psychologie Medicale Bruxelles, Belgium: Techniques

CERCETĂRI FARMACOCLINICE (selectiv)

Investigator principal în următoarele studii multicentrice internaționale:

1. European First Episode of Schizophrenia Trial (EUFEST), 2002-2006

14. A randomized, double-blind, placebo-controlled, parallel-group, comparative,

episodes associated with bipolar 1 disorder in adults subjects. Protocol TAK-375SL_301.

PARTICIPĂRI LA MANIFESTĂRI ȘTIINȚIFICE NAȚIONALE ȘI

1. 17 th Danube Symposium of Psychiatry, Timişoara-Romania, 24-27 Aprilie, 1996

27. Forumul de Psihiatrie 2005

LUCRĂRI IN-EXTENSO COTATE ISI

1. Vasile D, Vasiliu O. Management of affective symptoms and quality of life improvement

2. D.Vasile. Harm-reduction as risk decreasing strategy in heroin dependence. North Atlantic

3. Vasile D, Vasiliu O. Anticonvulsants for severe behavioral disturbances in Alzheimer

4. Vasile D, Vasiliu O. Management of Cognitive symptoms in dementia associated with

5. Vasile D, Vasiliu O. Matching Psychotropics to Neurobiological Mechanisms in the

6. Landolt K, Rossler W, Ajdacic-Gross V, Derks EM, Libiger J, Kahn RS, Fleischhacker

7. Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, Fleishhacker WW, Kahn RS,

8. Riecher-Rossler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS, Malik P,

9. Wobrock T, Falkai P, Schmeider-Axmann T, Hasan A, Galderisi S, Davidson M, Kahn RS,

13. Rybakowski JK, Vansteelandt K, Szafranski T, Thys E, Jarema M, Wolfgang

14. Landolt K, Rossler W, Burns T, Ajdacic-Gross V, Galderisi S, Libiger J, Naber D, Derks

16. Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW,

22. Dima L, Vasile D, Rogozea L, Zia-Ul-Haq M, Bukhari SA, Moga M. Self-perception of

23. Heun R, Ahokas A, Boyer P, Gimenez-Montesinos N, Pontes-Soares F, Olivier V,

24. Vasile D. Harm-reduction as risk decreasing strategy in heroin dependence. North

25. Anand R, Geffen Y, Vasile D, Dan I. An open-label tolerability study of BL-1020

STUDII PUBLICATE ÎN REZUMAT COTATE ISI

1. Early pharmacological intervention in first episode schizophrenia

2. Reboxetine in the treatment of elderly inpatients with Major Depressive Disorder

3. Efficacy of venlafaxine in the treatment of generalized anxiety disorder

4. Efficacy of Rivastigmine on cognitive and behavioural symptoms in patients with